← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
RKDA
Arcadia Biosciences, Inc.
Valuation N/A
Energy Risk 43 · Elevated
Price$0.43
Model IV—
P/IV—
Market implies +20.3%/yr vs model +0.0% · above model
RKLB
Rocket Lab Corp
Valuation N/A
Consumer Cyclical Risk 35 · Moderate
Price$63.55
Model IV—
P/IV—
Market implies +121.2%/yr vs model +8.0% · above model
RKT
Rocket Companies, Inc.
Valuation N/A
Financial Services Risk 62 · High
Price$13.18
Model IV—
P/IV—
Market implies +59.6%/yr vs model +0.0% · above model
RLAY
Relay Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$18.87
Model IV—
P/IV—
Market implies +64.5%/yr vs model +50.0% · above model
RLMD
RELMADA THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$4.52
Model IV—
P/IV—
Limited data — see page
RLTY
Cohen & Steers Real Estate Opportunities & Income Fund
Valuation N/A
Unknown
Price$14.85
Model IV—
P/IV—
Limited data — see page
RLYB
Rallybio Corp
Valuation N/A
Healthcare Risk 27 · Moderate
Price$16.88
Model IV—
P/IV—
Market implies +56.9%/yr vs model +15.0% · above model
RMAX
RE/MAX Holdings, Inc.
Valuation N/A
Real Estate Risk 63 · High
Price$12.36
Model IV—
P/IV—
Limited data — see page
RMCF
Rocky Mountain Chocolate Factory, Inc.
Valuation N/A
Consumer Defensive Risk 28 · Moderate
Price$0.90
Model IV—
P/IV—
Market implies +6.6%/yr vs model +8.0% · in line
RMI
RiverNorth Opportunistic Municipal Income Fund, Inc.
Valuation N/A
Unknown
Price$14.57
Model IV—
P/IV—
Limited data — see page
RMIX
Suncrete, Inc.
Valuation N/A
Industrials Risk 58 · Elevated
Price$13.36
Model IV—
P/IV—
Limited data — see page
RMM
RiverNorth Managed Duration Municipal Income Fund, Inc.
Valuation N/A
Unknown
Price$13.85
Model IV—
P/IV—
Limited data — see page
RMMZ
RiverNorth Managed Duration Municipal Income Fund II, Inc.
Valuation N/A
Unknown
Price$14.18
Model IV—
P/IV—
Limited data — see page
RMSG
Real Messenger Corp
Valuation N/A
Technology Risk 33 · Moderate
Price$0.33
Model IV—
P/IV—
Limited data — see page
RMSGW
Real Messenger Corp
Valuation N/A
Technology Risk 62 · High
Price$0.04
Model IV—
P/IV—
Limited data — see page
RMT
ROYCE MICRO-CAP TRUST, INC.
Valuation N/A
Unknown
Price$13.44
Model IV—
P/IV—
Limited data — see page
RNA
Atrium Therapeutics, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$10.36
Model IV—
P/IV—
Limited data — see page
RNAC
Cartesian Therapeutics, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$8.19
Model IV—
P/IV—
Market implies +104.6%/yr vs model +2.0% · above model
RNAZ
Transcode Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.60
Model IV—
P/IV—
Limited data — see page
RNGT
Range Capital Acquisition Corp II
Valuation N/A
Financial Services
Price$10.17
Model IV—
P/IV—
Limited data — see page
RNGTU
Range Capital Acquisition Corp II
Valuation N/A
Financial Services
Price$10.46
Model IV—
P/IV—
Limited data — see page
RNGTW
Range Capital Acquisition Corp II
Valuation N/A
Financial Services
Price$0.30
Model IV—
P/IV—
Limited data — see page
RNP
COHEN & STEERS REIT & PREFERRED & INCOME FUND INC
Valuation N/A
Unknown
Price$19.67
Model IV—
P/IV—
Limited data — see page
RNTX
Rein Therapeutics, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.79
Model IV—
P/IV—
Limited data — see page
RNW
ReNew Energy Global plc
Valuation N/A
Utilities
Price$6.83
Model IV—
P/IV—
Limited data — see page
RNWWW
ReNew Energy Global plc
Valuation N/A
Utilities
Price$0.00
Model IV—
P/IV—
Limited data — see page
RNXT
RenovoRx, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$1.76
Model IV—
P/IV—
Market implies +48.2%/yr vs model +15.0% · above model
ROIV
Roivant Sciences Ltd.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$40.82
Model IV—
P/IV—
Market implies +144.2%/yr vs model +2.0% · above model
ROMA
Roma Green Finance Ltd
Valuation N/A
Industrials Risk 38 · Moderate
Price$9.44
Model IV—
P/IV—
Market implies +88.4%/yr vs model +15.0% · above model
ROOT
Root, Inc.
Valuation N/A
Financial Services Risk 66 · High
Price$53.60
Model IV—
P/IV—
Limited data — see page
RPGL
Republic Power Group Ltd
Valuation N/A
Technology
Price$1.46
Model IV—
P/IV—
Limited data — see page
RPID
RAPID MICRO BIOSYSTEMS, INC.
Valuation N/A
Healthcare Risk 50 · Elevated
Price$1.23
Model IV—
P/IV—
Market implies +21.1%/yr vs model +9.7% · above model
RQI
COHEN & STEERS QUALITY INCOME REALTY FUND INC
Valuation N/A
Unknown
Price$11.81
Model IV—
P/IV—
Limited data — see page
RR
RICHTECH ROBOTICS INC.
Valuation N/A
Industrials Risk 40 · Elevated
Price$1.65
Model IV—
P/IV—
Market implies +67.6%/yr vs model +2.0% · above model
RREV
RRE Ventures Acquisition Corp.
Valuation N/A
Financial Services
Price$9.91
Model IV—
P/IV—
Limited data — see page
RREVU
RRE Ventures Acquisition Corp.
Valuation N/A
Financial Services
Price$10.10
Model IV—
P/IV—
Limited data — see page
RREVW
RRE Ventures Acquisition Corp.
Valuation N/A
Financial Services
Price$0.45
Model IV—
P/IV—
Limited data — see page
RSF
RiverNorth Capital & Income Fund, Inc.
Valuation N/A
Unknown
Price$14.47
Model IV—
P/IV—
Limited data — see page
RTAC
Renatus Tactical Acquisition Corp I
Valuation N/A
Financial Services
Price$10.44
Model IV—
P/IV—
Limited data — see page
RTACU
Renatus Tactical Acquisition Corp I
Valuation N/A
Financial Services
Price$10.73
Model IV—
P/IV—
Limited data — see page
RTACW
Renatus Tactical Acquisition Corp I
Valuation N/A
Financial Services
Price$0.70
Model IV—
P/IV—
Limited data — see page
RTB
RTB Digital, Inc.
Valuation N/A
Industrials Risk 55 · Elevated
Price$7.11
Model IV—
P/IV—
Market implies -3.2%/yr vs model +2.0% · below model
RTO
RENTOKIL INITIAL PLC /FI
Valuation N/A
Industrials Risk 33 · Moderate
Price$22.37
Model IV—
P/IV—
Limited data — see page
RUM
Rumble Inc.
Valuation N/A
Technology Risk 35 · Moderate
Price$8.20
Model IV—
P/IV—
Market implies +33.6%/yr vs model +50.0% · below model
RVI
Robinhood Ventures Fund I
Valuation N/A
Unknown
Price$28.28
Model IV—
P/IV—
Limited data — see page
RVMD
Revolution Medicines, Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$203.77
Model IV—
P/IV—
Market implies +126.5%/yr vs model +15.0% · above model
RVMDW
Revolution Medicines, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$11.29
Model IV—
P/IV—
Market implies +91.9%/yr vs model +2.0% · above model
RVSN
Rail Vision Ltd.
Valuation N/A
Consumer Cyclical Risk 33 · Moderate
Price$3.89
Model IV—
P/IV—
Market implies +85.5%/yr vs model +13.8% · above model
RVT
ROYCE SMALL-CAP TRUST, INC.
Valuation N/A
Unknown
Price$17.78
Model IV—
P/IV—
Limited data — see page
RXO
RXO, Inc.
Valuation N/A
Industrials Risk 40 · Elevated
Price$19.49
Model IV—
P/IV—
Market implies +40.3%/yr vs model +5.4% · above model
RXRX
RECURSION PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$3.20
Model IV—
P/IV—
Market implies +35.4%/yr vs model +50.0% · below model
RY
ROYAL BANK OF CANADA
Valuation N/A
Financial Services Risk 59 · Elevated
Price$205.90
Model IV—
P/IV—
Limited data — see page
RYAAY
RYANAIR HOLDINGS PLC
Valuation N/A
Industrials Risk 59 · Elevated
Price$53.80
Model IV—
P/IV—
Limited data — see page
RYAN
RYAN SPECIALTY HOLDINGS, INC.
Valuation N/A
Financial Services
Price$38.12
Model IV—
P/IV—
Limited data — see page
RYET
Ruanyun Edai Technology Inc.
Valuation N/A
Technology Risk 27 · Moderate
Price$0.72
Model IV—
P/IV—
Market implies +25.0%/yr vs model +2.0% · above model
RYM
RYTHM, Inc.
Valuation N/A
Basic Materials Risk 57 · Elevated
Price$21.65
Model IV—
P/IV—
Market implies +78.6%/yr vs model +0.0% · above model
RZLT
Rezolute, Inc.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$4.22
Model IV—
P/IV—
Limited data — see page
RZLVW
REZOLVE AI PLC
Valuation N/A
Technology Risk 71 · High
Price$0.68
Model IV—
P/IV—
Market implies +30.9%/yr vs model +50.0% · below model
SA
SEABRIDGE GOLD INC
Valuation N/A
Basic Materials Risk 32 · Moderate
Price$29.30
Model IV—
P/IV—
Limited data — see page
SAAQ
Space Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$10.10
Model IV—
P/IV—
Limited data — see page